ArticleEuropean journal of cancer (Oxford, England : 1990)2017
iRECIST: A clarification of tumour response assessment in the immunotherapy era.
Article in European journal of cancer (Oxford, England : 1990), 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
15 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Relationship Between Progression-Free Survival, Objective Response Rate, and Overall Survival in Clinical Trials of PD-1/PD-L1 Immune Checkpoint Blockade: A Meta-Analysis.Clinical pharmacology and therapeutics · 2020Pooled it
- Comparing RECIST 1.1 and iRECIST in advanced melanoma patients treated with pembrolizumab in a phase II clinical trial.European radiology · 2021Trial
- The Role of 18F-FDG PET/CT in Monitoring Immunotherapy Response in Non-Small Cell Lung Cancer: Current Evidence and Challenges: A Narrative Review.Diagnostics (Basel, Switzerland) · 2025Review
- Glyco-signatures in patients with advanced lung cancer during anti-PD-1/PD-L1 immunotherapy.Acta biochimica et biophysica Sinica · 2024Article
- Pseudoprogression in CAR-T cell therapy for solid tumor: Case report.Frontiers in immunology · 2024Article
- Imaging Follow-Up of Nonsurgical Therapies for Lung Cancer:AJR. American journal of roentgenology · 2023Review
- Elevated tumor markers for monitoring tumor response to immunotherapy.EClinicalMedicine · 2022Article
- Novel Biomarkers of Dynamic Blood PD-L1 Expression for Immune Checkpoint Inhibitors in Advanced Non-Small-Cell Lung Cancer Patients.Frontiers in immunology · 2021Article
- Patterns of progression in patients treated for immuno-oncology antibodies combination.Cancer immunology, immunotherapy : CII · 2021Article
- Overall survival benefit of continuing immune checkpoint inhibitors treatment post dissociated response in patients with advanced lung cancer.Journal of cancer research and clinical oncology · 2020Article
- Immune Response Evaluation and Treatment with Immune Checkpoint Inhibitors Beyond Clinical Progression: Response Assessments for Cancer Immunotherapy.Current oncology reports · 2020Review
- Role of medical imaging for immune checkpoint blockade therapy: From response assessment to prognosis prediction.Cancer medicine · 2019Review
- The Evaluation of Response to Immunotherapy in Metastatic Renal Cell Carcinoma: Open Challenges in the Clinical Practice.International journal of molecular sciences · 2019Review
- [Radiological response assessment of modern immunotherapy using iRECIST].Der Radiologe · 2017Review
- Review
Corrections and comments
- Commented on by
- Comment on
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
PubMed holds no abstract for this paper.
Indexed as
Identifiers
28385325What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.